Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medincell's score of 38 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Medincell reported approximately 7,070,000 kg CO2e in Scope 3 emissions, with significant contributions from purchased goods and services (about 5,053,000 kg CO2e), business travel (about 767,000 kg CO2e), and capital goods (about 707,000 kg CO2e). The previous year, 2023, saw similar Scope 3 emissions, totalling around 6,000,000 kg CO2e, with the largest sources being purchased goods and services (about 5,120,000 kg CO2e) and business travel (about 248,000 kg CO2e). In 2022, Medincell disclosed a total of 666,074,000 kg CO2e in emissions, although the specific scopes were not detailed. For Scope 1 and 2 emissions, the company reported 9,820 kg CO2e in 2022, with no emissions recorded for Scope 1. Despite these figures, Medincell has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company’s climate strategy appears to be in its early stages, focusing on transparency in emissions reporting without established reduction goals. Overall, Medincell's emissions data reflects a significant reliance on Scope 3 emissions, highlighting the need for a comprehensive approach to climate commitments and reduction strategies in the future.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - |
| Scope 2 | 8,380 | 0,000 | 0,000 | 0,000 | - | - |
| Scope 3 | - | - | - | - | 0,000,000 | 0,000,000 |
Medincell's Scope 3 emissions, which increased by 10% last year and increased by approximately 10% since 2023, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 73% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medincell has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
